Welcome to our dedicated page for Quince Therapeutics SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quince Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quince Therapeutics's regulatory disclosures and financial reporting.
Quince Therapeutics completed the acquisition of Orphai Therapeutics in a stock‑for‑stock merger and simultaneously arranged a large private financing to refocus the company on rare pulmonary diseases. Orphai holders received 3,258,517 Quince common shares and 67,101.235 Series C non‑voting convertible preferred shares, plus options and replacement warrants.
The company agreed to sell 144,200.633 additional Series C preferred shares and Financing Warrants to purchase 72,100.322 Series C preferred shares for about $115 million upfront and up to roughly $72 million more if the warrants are fully exercised. After the deal and Financing, Quince pre‑transaction holders would own about 6.9% of common stock, Orphai holders 31.9%, and new investors 61.2% on a fully diluted basis, while management expects cash runway through the end of 2028 to advance LAM‑001 through multiple Phase 2 milestones.
Quince Therapeutics ownership update: Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 4,528,302 shares of common stock, representing 7.52% of shares outstanding as of March 31, 2026. The reported shares include 4,528,302 shares that may be acquired within sixty days through the exercise of convertible securities.
Quince Therapeutics reported a sharp swing to profitability for the three months ended March 31, 2026, with net income of $35.9 million versus a $15.0 million loss a year earlier. The profit was driven mainly by non-cash fair value gains on contingent consideration, warrants, and debt.
The company’s Phase 3 NEAT trial of its lead asset eDSP in A-T failed to meet primary and secondary endpoints, and Quince has ceased development of eDSP in all indications. This triggered a $67.8 million impairment of intangible assets and the elimination of up to $485.0 million in potential contingent payments from the EryDel acquisition.
Cash and cash equivalents were $18.2 million as of March 31, 2026, supported by $15.0 million of net proceeds from at-the-market share sales and settlement of the EIB loan for approximately $5.5 million. Management states that existing cash is not sufficient to fund at least 12 months of operations, concluding that substantial doubt exists about Quince’s ability to continue as a going concern while it pursues strategic alternatives and restructuring.
Quince Therapeutics, Inc. reports that Nasdaq has informed the company it has regained compliance with the Nasdaq Global Select Market minimum bid price requirement under Listing Rule 5450(a)(1). The company’s common stock closed at $1.00 or more for 10 consecutive business days from April 13 through April 24, 2026.
The company remains out of compliance with Nasdaq’s market value of listed securities requirement under Listing Rule 5450(b)(2)(A), which requires at least $50,000,000. Quince has until September 14, 2026 to regain compliance with this MVLS requirement, and there is no assurance it will do so or maintain compliance with other listing standards.
Quince Therapeutics, Inc. is holding a virtual 2026 annual stockholder meeting on June 11, 2026 at 10:00 a.m. Pacific Time to vote on several key proposals.
Stockholders will elect one Class I director, consider a major reverse stock split of common stock at a ratio between 1-for-10 and 1-for-100, and vote on ratifying BDO USA, P.C. as auditor for 2026. They will also cast an advisory vote on executive compensation and approve potential adjournment to solicit more proxies. Stockholders of record as of April 23, 2026, when 16,300,740 common shares were outstanding, are entitled to vote.
Quince Therapeutics, Inc. reported that its Board of Directors increased its size to four members and appointed June Bray as a Class I independent director effective April 22, 2026. She will serve until the 2026 Annual Meeting of Stockholders, or earlier if she departs the role.
Bray has been designated an independent director under Nasdaq rules and will serve on the Nominating & Governance, Audit, and Compensation Committees. Under the company’s Outside Director Compensation Policy, she will receive a $38,000 annual cash retainer for Board service, plus annual retainers of $7,500 for Nominating & Governance, $5,500 for Audit, and $4,000 for Compensation Committee work, without an option grant at appointment. She will also enter into the company’s standard indemnification agreement for directors.
Quince Therapeutics, Inc. is soliciting shareholder approval to amend its certificate of incorporation to permit a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-100, with the exact ratio set at the Board’s discretion.
The 2026 virtual Annual Meeting is scheduled for June 11, 2026; the Record Date for voting is April 23, 2026. The Board says the split is intended to help regain or maintain compliance with Nasdaq’s $1.00 minimum bid price rule and addresses a prior 1-for-10 split effected April 10, 2026. Authorized shares remain 250,000,000.
Quince Therapeutics, Inc. reports that its lead asset eDSP failed to meet primary and key secondary endpoints in the pivotal NEAT Phase 3 trial for A‑T, leading the company to discontinue all development of eDSP and other product candidates. With no active pipeline and limited resources, Quince is now primarily focused on preserving cash and exploring strategic alternatives, especially a potential reverse merger, for which it has hired LifeSci Capital as exclusive financial advisor.
The company flags substantial doubt about its ability to continue as a going concern and plans to seek additional equity or debt financing, including potential sales of common stock under an at‑the‑market agreement. Quince also discloses Nasdaq notices for noncompliance with minimum bid price and market value requirements and warns that delisting could occur. As of December 31, 2025, Quince had $17.8 million in cash, cash equivalents and short‑term investments, an accumulated deficit of $460.5 million, and a net loss of $84.0 million for 2025, while continuing to evaluate restructuring options and potential asset sales.
Quince Therapeutics, Inc. is implementing a reverse stock split of its common stock at a 1-for-10 ratio. Every ten shares will be automatically combined into one share, with no change to the $0.001 par value or basic rights of the common stock.
The reverse split becomes effective at 11:59 pm Eastern Time on April 10, 2026, and the shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market on April 13, 2026 under the same symbol QNCX but a new CUSIP 22053A206. Immediately after the split, approximately 16,300,795 shares of common stock will be issued and outstanding. Fractional shares will not be issued; affected stockholders will receive cash in lieu of fractional shares.